HCV Core Antigen ELISA Kit

Name: HCV Core Antigen ELISA Kit
SKU: DEIABL55
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Purified virus or unpurified viral supernatant

Species Reactivity

Detection Method

sELISA

Storage

Upon receiving, aliquot and store recombinant HCVcAg Standard at -20°C and avoid freeze/thaw. Store all other components at 4°C.

General Description

Hepatitis C is an infection of the liver caused by the hepatitis C virus. HCV is transmitted by exposure to infectious blood; forms of transmission include unprotected sexual activity, blood transfusion, mother-to-infant transmission, or occupational exposure to blood. The acute illness causes liver inflammation, liver fibrosis, vomiting and jaundice, while chronic HCV infection often leads to liver cirrhosis and failure.
An estimated 270-300 million people worldwide have been infected with hepatitis C. At least 75% of people infected will develop chronic hepatitis C and have it the rest of their lives.

Diagnosis of chronic hepatitis C virus (HCV) infection has long been based on HCV serology and detection of HCV antibodies. With the development of therapies for chronic HCV infection, including interferon and ribavirin, quantitative detection of HCV has been used increasingly as the most important marker for monitoring HCV titer, disease progression, and assessing antiviral treatment. Several assays for the quantitative measurement of HCV DNA have been developed, such as PCR based nucleic acid amplification assays. However, these methods tend to be cumbersome and expensive.

The HCV Core Antigen ELISA Kit is an enzyme immunoassay developed for detection and quantitation of the HCV core protein. The kit has detection sensitivity limit of 1 ng /mL HCVcAg. Each kit provides sufficient reagents to perform up to 96 assays including standard curve and HCV samples.

Citations

Have you cited DEIABL55 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Prevalence of hepatitis B seromarkers and hepatitis C antibodies in blood donors in Basra, Iraq

BMJ OPEN GASTROENTEROLOGY

Authors: Al-Rubaye, Ali; Tariq, Ziad; Alrubaiy, Laith

Abstract

Background: Transfusion-caused hepatitis remains a major problem in Iraq. Therefore, testing for hepatitis B surface antigen (HBsAg), antibodies to hepatitis B core antigen (anti-HBc) and antibodies to hepatitis C antigen (anti-HCV) is a very important preventative measure. The objective of this study was to establish the prevalence of hepatitis B and C virus seromarkers among blood donors as a foundation for safe blood transfusion in Iraq. Methods: A cross-sectional observational study was conducted in the blood banks in Basra, Iraq from 1 January to 31 December 2013. Blood samples were collected and were tested for HBsAg, anti-HBc and anti-HCV using standard laboratory techniques. Results: A total of 69 915 blood donors were enrolled for the study. A total of 1625 (2.3%) donors have shown serological evidence for hepatitis B virus infection; of those donors, 125 (0.2%) showed a positive test result for both anti-HBc and HBsAg while 1475 (2.1%) had positive anti-HBc results as the only positive test for HBV infection. There was no significant difference between males and females (p=0.28). The prevalence of anti-HCV was 0.1%. Conclusions: This is the first large population study of its kind in Basra, Iraq. The prevalence of hepatitis B and C among blood donors is very low in Basra. Around 2% of blood donors had anti-HBc as the only serological evidence of HBV infection. Inclusion of anti-HBc in routine screening of blood donors in Iraq should be encouraged.

Risk of Hepatitis B Virus Reactivation Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection

JOURNAL OF CLINICAL GASTROENTEROLOGY

Authors: Yanny, Beshoy T.; Latt, Nyan L.; Saab, Sammy; Han, Steven; Choi, Gina; Kramer, Jason; Sahota, Amandeep K.

Abstract

Background: Direct acting antiviral (DAA) agents are the standard of care for treatment of hepatitis C virus (HCV)-infected individuals. Hepatitis B virus (HBV) reactivation during HCV treatment has been reported, the incidence and clinical outcome remains unclear. The aim of our study is to examine the risk of HBV reactivation in actively infected or previously exposed patients during or after HCV treatment with DAAs. Methods: Adults with chronic HCV infection previously exposed or actively infected with HBV and treated with DAAs between December 2015 to 2016 were included. Electronic medical records were reviewed for HCV treatment dates, HCV treatment response, DAA used, HBV status, and concurrent HBV treatment. Primary end-point was to determine the risk of HBV reactivation during or up to 3 months after DAA treatment. Results: We identified 283 patients, and 100% of patients completed HCV treatment with ledipasvir-sofosbuvir. 93% had HCV genotype-1 of whom 91% achieved sustained viral response at 12 weeks post-treatment (SVR-12). In total, 7% had HCV genotype-4 who achieved SVR-12 of 84%. Mean (+/- SD) age was 59.7 (+/- 7) years, and 58% were male. A total of 45% of patients had hepatitis B core antibody (HBcAb) positive and hepatitis B surface antigen (HBsAg) negative. In total, 55% of patients had a positive HBsAg before HCV DAA treatment. No HBV reactivation was encountered in the (HBcAb) positive HBsAg-negative cohort nor in the (HBsAg) positive group with 95% confidence interval (0-0.023) and (0-0.019), respectively. Conclusion: In our study of patients with HCV and isolated hepatitis B core or HBsAg positivity, no HCV patients treated with DAA experienced HBV reactivation.